Premium
Late genitourinary and gastrointestinal toxicity after magnetic resonance image‐guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy
Author(s) -
Albert Michele,
Tempany Clare M.,
Schultz Delray,
Chen MingHui,
Cormack Robert A.,
Kumar Sanjaya,
Hurwitz Mark D.,
Beard Clair,
Tuncali Kemal,
O'Leary Michael,
Topulos George P.,
Valentine Kristin,
Lopes Lynn,
Kanan Angela,
Kacher Daniel,
Rosato James,
Kooy Hanne,
Jolesz Ferenc,
CarrLocke David L.,
Richie Jerome P.,
D'Amico Anthony V.
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11595
Subject(s) - medicine , brachytherapy , prostate cancer , prostate , genitourinary system , radiation therapy , common terminology criteria for adverse events , external beam radiotherapy , magnetic resonance imaging , urology , radiology , hormonal therapy , surgery , cancer
BACKGROUND This study was designed to estimate the rates of late genitourinary (GU) and rectal toxicity after magnetic resonance image (MRI)‐guided prostate brachytherapy exclusively or in conjunction with external beam radiation therapy (EBRT). METHODS Between November 1997 and April 2002, 201 patients with category T1C prostate carcinoma (according to the 2002 American Joint Committee on Cancer staging criteria), prostate specific antigen levels < 10 ng/mL, and biopsy Gleason score 3 + 4 disease were treated with MRI‐guided brachytherapy exclusively or in conjunction with EBRT. The MRI‐guided technique was designed to spare the urethra based on delivery of the prescription dose to the peripheral zone exclusively. The Kaplan–Meier method was used to estimate rates of freedom from late GU and rectal toxicity. Comparisons were made using a log‐rank test. RESULTS At a median follow‐up of 2.8 years (range, 0.5–5.0 years), the 4‐year estimates of rectal bleeding requiring coagulation for patients who underwent implantation therapy, compared with patients who received combined‐modality therapy, were 8% versus 30%, respectively (log‐rank P value = 0.0001). Although erectile dysfunction was common (range, 82–93%), with the use of sildenafil citrate (Viagra®), it was estimated that at least two‐thirds of patients had erectile function comparable to or superior to baseline function, independent of whether they received monotherapy or combined‐modality therapy ( P = 0.46). The 4‐year estimate of freedom from radiation cystitis was 100% versus 95% ( P = 0.01) for patients who received monotherapy and patients who received combined‐modality therapy, respectively. No urethral strictures were observed, and no patients underwent postimplantation transurethral resection of the prostate. CONCLUSIONS In the current study, rectal bleeding after MRI‐guided prostate brachymonotherapy was infrequent, and urethral and bladder toxicity is reported to be rare and may be attributed to the urethral‐sparing technique of the MRI‐guided approach. Cancer 2003;98:949–54. © 2003 American Cancer Society. DOI 10.1002/cncr.11595